GEN Exclusives

More »

Feature Articles

More »
Jul 1, 2009 (Vol. 29, No. 13)

Upgrading Cell-Based Viability Assays

Novel Approaches More Accurately Reflect the In Vivo Human State

  • Monitoring Cellular Performance

    Click Image To Enlarge +
    Seahorse Bioscience’s XF96 Extracellular Flux Analyzer simultaneously measures the two major energy yielding pathways—aerobic respiration and glycolysis—in a convenient, microplate format.

    “Mitochondria were long neglected as a tool for cell-based assays,” says Steve Chomicz, vp of sales and marketing at Seahorse Bioscience. Although their central roles in cancer and many other pathological processes have been long recognized, the tools for studying mitochondrial function have hardly changed since the 1930s.

    According to Chomicz, many cell-based assays measure features such as cell permeability, and in doing so miss the vital contribution of mitochondrial health to cell function. “We perform the equivalent of a stress test on our cells that reveals dysfunctional respiratory capacity,” he explains.

    It is now possible to monitor myocytes grown under conditions that mimic a lean or obese model in order to develop a realistic cell-based assay for studying drugs that may affect metabolism. This includes the measurement of cellular respiration, revealing important cellular responses not detectable with other viability assays. An important feature of the XF platform is its noninvasive, physiologic measurement for primary or cultured cells, allowing the cells to be recycled for other purposes.

  • The Future of Cell-Based Assays

    According to Andrew Niles, Ph.D., and his colleagues at Promega, there is a tendency within the industry to move to bioluminescent assays and away from traditional absorbance and fluorescence chemistries.

    Bioluminescent proteins have a number of advantages over conventional organic fluorescent dyes. They are highly restricted within the kingdom of living organisms, are much more sensitive, and are rarely subject to quenching or interference through autofluorescence. However, new ways of examining cellular response are on the horizon, and being label-free is especially tantalizing.


Readers' Comments

Posted 07/10/2009 by Sr. Director, Business Development

Very insightful article that highlights multiple new technologies being advanced. One concern that I do not see being addressed is the drive to make our in vitro assays more physiologically relevant by removing and replacing non-human components when possible. Cells do b ehave differently when cultured on plastic or Matrigel when compared to fully human ECMs. There are dramatic morphological as well as molecular gene expression differences that lead to aberrant and misleading results. Minimizing these impacts on in vitro assays and maximizing human physiological relevance is the future of cell-based assays.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?